HighVista Strategies LLC Purchases 189,647 Shares of GH Research PLC $GHRS

HighVista Strategies LLC lifted its position in GH Research PLC (NASDAQ:GHRS) by 363.0% in the 3rd quarter, Holdings Channel reports. The fund owned 241,894 shares of the company’s stock after acquiring an additional 189,647 shares during the quarter. HighVista Strategies LLC’s holdings in GH Research were worth $3,459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Osaic Holdings Inc. boosted its position in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. bought a new position in GH Research in the second quarter worth $79,000. Virtus Investment Advisers LLC bought a new position in GH Research in the second quarter worth $89,000. BNP Paribas Financial Markets lifted its position in GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after buying an additional 10,600 shares during the period. Finally, Man Group plc bought a new stake in shares of GH Research during the 3rd quarter valued at $315,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GHRS shares. Guggenheim set a $34.00 target price on shares of GH Research and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Canaccord Genuity Group lifted their price target on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright boosted their price objective on shares of GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. TD Cowen restated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Finally, Royal Bank Of Canada lifted their target price on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.13.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $14.95 on Monday. GH Research PLC has a 1 year low of $7.98 and a 1 year high of $19.51. The company has a market cap of $927.35 million, a P/E ratio of -18.69 and a beta of 1.00. The stock’s fifty day moving average price is $15.72 and its 200-day moving average price is $14.34.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06. On average, sell-side analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.